Viking Therapeutics emerges as a competitor
CR | Stock | fake images biotechnology company Viking therapeutics has become a strong potential entrant (or acquisition target) in…
Eli Lilly and company
Here's Eli Lilly's Competitive Advantage in GLP-1 Obesity Drugs and Abbott's Supporting Role
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
TJX quarter delivers and what Cramer expects to hear from Salesforce
Every weekday, the CNBC Investing Club with Jim Cramer hosts a “Morning Meeting” livestream at 10:20 a.m. ET. Here's a…
New Pet Medications Look Much More Like Human Medications
If you want to understand how different the human and animal drug and vaccine industries have historically been, you don't…
Liver disease is the new use of weight loss drugs
Image of a healthy liver not ravaged by fatty liver disease. BSIP | fake images Do you think a friend…
Viking Therapeutics' weight loss drug shows promising trial results
CR | Stock | fake images Actions of Viking therapeutics surged more than 80% in premarket trading on Tuesday after…
Gene Therapies for Sickle Cell Casgevy Lyfgenia Insurance Cost Issues
Patient's blood sample tested positive for sickle cell anemia. Kitsawet Saethao | Stock | fake images The approval of two…
What you need to know about health coverage for new weight loss drugs
Many American companies are dealing with health insurance coverage issues for workers when it comes to GLP-1 weight loss drugs.…
In this fast-paced bull market, we are increasing our Club price targets by 4 stocks
It's been difficult to keep up. That's the story of this year's big stock winners. They keep winning and winning…
What Eli Lilly Investors Can Learn from the Slow Launch of a Rival Drug
Club holding company Eli Lilly hopes to win approval for its Alzheimer's treatment in the coming weeks, but investors looking…